<DOC>
	<DOCNO>NCT02055703</DOCNO>
	<brief_summary>This study single-center , open-label , drug-drug interaction study healthy male female subject . The study consist 3 part : A , B , C. In Part A , effect itraconazole rifampin pharmacokinetics ( PK ) E2609 metabolite assess . Approximately 32 subject assign 1 2 treatment group ( itraconazole rifampin ) equal number , approximately 16 subject per group . In Part B , effect steady-state dose E2609 PK digoxin assess approximately 18 subject . In Part C , effect donepezil administer combination , 2 hour , E2609 dose PK E2609 metabolite , assess approximately 24 subject .</brief_summary>
	<brief_title>A 3-Part , Open-Label , Drug-Drug Interaction Study Concomitant Administration E2609 With Itraconazole , Rifampin , Digoxin , Donepezil</brief_title>
	<detailed_description />
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Inclusion Criteria 1 . Healthy male female subject age 1855 year inclusive time inform consent 2 . Provide write informed consent 3 . Willing able comply aspect protocol Exclusion Criteria 1 . Any history seizure epilepsy ( include history simple febrile seizure childhood ) disturbance consciousness likely due seizure 2 . A prolonged QT/QTc interval ( QTc great 450 m ) demonstrate mean triplicate electrocardiogram ( ECGs ) , record least 1 min apart , Screening Baseline Periods 3 . Evidence clinically significant disease ( eg , psychiatric disorder disorder gastrointestinal tract , liver , kidney , respiratory system , endocrine system , hematological system , neurological system , cardiovascular system ) opinion investigator ( ) could affect subject 's safety interfere study assessment subject congenital abnormality metabolism within 4 week dose . 4 . Any laboratory abnormality consider clinically significant investigator , may require investigation treatment 5 . Clinically significant illness require medical treatment within 8 week clinically significant infection within 4 week dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Healthy Subjects</keyword>
</DOC>